» Articles » PMID: 24935080

Impaired Function of CD19(+) CD24(hi) CD38(hi) Regulatory B Cells in Patients with Pemphigus

Overview
Journal Br J Dermatol
Specialty Dermatology
Date 2014 Jun 18
PMID 24935080
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pemphigus is an organ-specific autoimmune bullous disease.

Objectives: To determine the role of regulatory B cells (Bregs) in patients with pemphigus.

Methods: The frequency of the occurrence of CD19(+) CD24(hi) CD38(hi) Bregs was detected from 34 patients with pemphigus and 20 healthy controls. Interleukin (IL)-10 secretion was processed after stimulating B cells. Specific antidesmoglein antibody (Ab) titres and their subclasses were also measured. Ab response and cytokine production from peripheral blood mononuclear cells (PBMCs) with or without Bregs were analysed.

Results: The number of Bregs was significantly increased in patients with pemphigus compared with healthy controls (15 ± 7% vs. 9 ± 3%; P < 0·01) and the proportion of Bregs in the active groups (newly diagnosed and chronic active patients) was significantly higher than in remittent individuals (16 ± 7% vs. 13 ± 8%; P = 0·04). The IL-10-producing B cells were significantly increased upon stimulation both in patients and in healthy controls. However, the increase ratio of IL-10-producing B cells between short- and long-term stimulation was significantly lower in patients with pemphigus (1·0-fold vs. 2·6-fold increase in control group; P < 0·01). Strikingly, Bregs from the controls were able to suppress interferon (IFN)-γ expression and T helper cell 1 (Th1) immune response (26% inhibition rate), while the suppressive function of Bregs from patients with pemphigus was significantly decreased (9% inhibition rate). There was no difference in Ab levels from PBMCs with or without Bregs after stimulation.

Conclusions: Bregs in patients with pemphigus are elevated but with defective regulatory function on Th1 cells.

Citing Articles

Revealing the role of regulatory b cells in cancer: development, function and treatment significance.

Ye R, Li S, Li Y, Shi K, Li L Cancer Immunol Immunother. 2025; 74(4):125.

PMID: 39998678 PMC: 11861783. DOI: 10.1007/s00262-025-03973-w.


From neglect to spotlight: the underappreciated role of B cells in cutaneous inflammatory diseases.

Lee E, Oh J Front Immunol. 2024; 15:1328785.

PMID: 38426103 PMC: 10902158. DOI: 10.3389/fimmu.2024.1328785.


Breg-Mediated Immunoregulation in the Skin.

Zheremyan E, Ustiugova A, Karamushka N, Uvarova A, Stasevich E, Bogolyubova A Int J Mol Sci. 2024; 25(1).

PMID: 38203754 PMC: 10778726. DOI: 10.3390/ijms25010583.


Continued dysregulation of the B cell lineage promotes multiple sclerosis activity despite disease modifying therapies.

Londono A, Mora C F1000Res. 2023; 10:1305.

PMID: 37655229 PMC: 10467621. DOI: 10.12688/f1000research.74506.2.


Multiple Sclerosis Is Associated with Immunoglobulin Germline Gene Variation of Transitional B Cells.

Lomakin Y, Ovchinnikova L, Zakharova M, Ivanova M, Simaniv T, Kabilov M Acta Naturae. 2023; 14(4):84-93.

PMID: 36694905 PMC: 9844083. DOI: 10.32607/actanaturae.11794.